Skip to main content

Table 3 The prevalence (p) of HIV treatment failure based on HAART failure, immunological, virological, and clinical definition when the study omitted in Ethiopia

From: HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis

Study omitted

HAART failure P (95%CI)

Immunological failure P (95%CI)

Virological failure P (95%CI

Clinical failure P (95% CI)

Bokretsion BG et al./2017

15.3 (10.8–19.9)

9.7 (6.3–13.2)

4.5 (2.3–6.7)

5.6 (4.2–7.1)

Yassin S /2017

15.5 (10.9–20.1)

10.5 (6.9–14.1)

__

5.5 (4.1–7.1)

Zeleke A/2016

15.6 (11.0–20.2)

10.6 (7.0–14.1)

__

6.7 (4.9–8.4)

Yimer YT/2015

15.4 (10.8–19.9)

9.8 (6.4–13.3)

6.5 (2.7–10.3)

6.3 (4.4–8.2)

Bacha T et al./2012

16.1 (10.9–21.3)

10.5 (6.6–14.4)

__

6.4 (4.3–8.4)

Ayalew MB et al./2016

17.3 (13.5–21.2)

10.8 (7.1–14.4)

6.0 (2.9–9.2)

__

Sisay MM et al./2018

16.9 (12.6–21.2)

10.9 (7.7–14.1)

__

6.4 (4.4–8.4)

Tsegaye AT et al./2016

15.5 (10.9–20.1)

10.5 (6.9–14.1)

__

6.7 (5.0–8.4)

Teshome W/2015

__

9.8 (6.3–13.2)

__

__

Hailu GG et al./2015

__

10.5 (6.9–14.1)

4.4 (2.0–6.9)

__

Yayehirad AM et al./2013

__

9.3 (6.3–12.4)

__

__

Workneh N et al./2009

__

10.1 (6.6–13.6)

___

6.4 (4.6–8.2)

Sisay C et al./2017

15.2 (10.8–19.5)

9.8 (6.4–13.2)

6.4 (2.4–10.4)

6.5 (4.7–8.4)

Abdissa A et al./2014

__

__

5.6 (2.7–8.6)

__

Combined

15.8 (11.6–20.1)

10.2 (6.8–13.6)

5.6 (2.9–8.3)

6.3 (4.6–7.9)

  1. __ denotes no estimation due to lack of original studies